Eli Lilly Buys Psychedelic Startup | Business and Finance News

Eli Lilly just dropped a blockbuster $2.8 billion deal to buy psychedelic startup Atai Becker, signaling a massive leap in the race to revolutionize mental health treatment. AtaiBeckley’s late-stage DMT-based drug for treatment-resistant depression, plus other psychedelic pipelines including MDMA-related compounds, could reshape therapy for depression and PTSD. With the Trump administration already spotlighting psychedelics, this move reflects a broader cultural and scientific shift. Eli Lilly, already on a $10B+ acquisition spree this year with potential to hit $25B, is betting big on established, high-impact projects. AtaiBeckley’s stock soared over 30% in premarket trading — a clear vote of confidence from investors. This isn’t just a corporate play — it’s a pivotal moment in how we’ll treat mental illness in the years ahead. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2480804da292e0ea